Purpose-built for physicians GLP-1s hold promise in MS, but more rigorous examination is required Key takeaways: There is limited evidence of GLP-1 receptor agonist safety and efficacy in MS
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered attention for its dual benefits of blood sugar control and weight loss
This dual-pathway approach theoretically amplifies weight loss beyond what either drug achieves alone
Most healthcare professionals advise sticking with the same day each week to maintain consistent medication levels in your system and to establish a reliable routine that minimises the risk of missed doses
Try Inside Rx for up to 80% savings Inside Rx may be able to help you save up to 80% on your prescription medications including GLP-1s at 60,000 pharmacies nationwide
11 Research in rodents and humans has substantiated that GLP-1 receptor agonists have shown promising results in reducing alcohol consumption and preference through neurobiological impact on the mesolimbic reward pathways in the VTA and NAc by modulating neurotransmitters involved in addiction such as dopamine and glutamine
